Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the market?

The market size for restless leg syndrome has experienced swift growth in recent years. Projected to increase from $1.91 billion in 2024 to $2.17 billion in 2025, it boasts a compound annual growth rate (CAGR) of 13.8%. Factors contributing to this notable growth during the historic period include rising alcohol consumption rates, expanded health insurance coverage, the accessibility of over-the-counter medications, more public health programs, and a spike in mental health disorders.

What will be the market size in the future?

The market size of restless leg syndrome is anticipated to experience swift expansion in the coming years, escalating to a value of $3.59 billion by 2029 at a compound annual growth rate (CAGR) of 13.4%. The predicted growth during the forecast period can be credited to factors such as an upsurge in healthcare investments, awareness and educational initiatives, an increase in early disease detection, elevated government funding, and improved participation in clinical trials. Key trends during the forecast period involve the use of AI in creating personalized treatment plans, the introduction of advanced neurostimulation devices, application of deep learning algorithms for diagnosis, the use of brainwave modulation technology, and the adoption of wearable exoskeletons for facilitating leg movements.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/restless-leg-syndrome-global-market-report

What key factors are fueling the growth of the market?

Escalating instances of iron deficiency are predicted to stimulate the expansion of the restless leg syndrome market. Iron deficiency is a condition where the body doesn’t have enough iron to create substantial healthy red blood cells, resulting in symptoms such as tiredness, frailty, and pallid skin. The rise in iron deficiency is attributed to reasons like inadequate diet, blood loss, malabsorption ailments, and heightened iron needs during pregnancy or growth. Treatments for restless leg syndrome often involve adjustments in diet or iron supplements, which not only aid in easing the unpleasant urges and sensations but also aim to rectify the underlying iron deficiency by replenishing the body’s iron reserves, enhancing the production of red blood cells, and re-establishing appropriate neurological functions. For example, in January 2025, the National Health Service England, a government agency based in England, recorded that there were 191,927 admissions due to iron deficiency during 2023-24, marking an 11% surge in contrast to 2022-23. Consequently, the growing instances of iron deficiency contribute to the progression of the restless leg syndrome market.

What key areas define the segmentation of the global market?

The restless leg syndrome market covered in this report is segmented –

1) By Type: Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome

2) By Treatment Type: Medicine And Devices, Surgery

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By Application: Neurological Treatment, Sleep Disorders, Movement Disorders, Symptom Management

Subsegments:

1) By Primary Restless Legs Syndrome: Idiopathic Restless Legs Syndrome, Hereditary Restless Legs Syndrome

2) By Secondary Restless Legs Syndrome: Iron Deficiency-related Restless Legs Syndrome, Chronic Kidney Disease-related Restless Legs Syndrome, Pregnancy-related Restless Legs Syndrome, Medication-induced Restless Legs Syndrome

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21274&type=smp

Who are the dominant players expanding their reach in the market?

Major companies operating in the restless leg syndrome market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Novartis International AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter International Inc., Astellas Pharma Inc., UCB S.A., Kyowa Kirin Co Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Mundipharma International Limited, Azurity Pharmaceuticals LLC, Otsuka Pharmaceutical Co Ltd., Horizon Therapeutics plc, Mylan N.V., Apollo Pharmacy Limited

What emerging trends are influencing the growth of the market?

Prominent businesses in the Restless Leg Syndrome (RLS) market are prioritizing the creation of cutting-edge solutions, like innovative non-invasive treatments, to advance the management of symptoms and improve patient outcomes. Innovative non-invasive therapies describe trailblazing medical interventions that don’t involve surgery or breaking the skin, with a focus on alleviating various conditions via advanced methods such as electrical stimulation, light therapy, or external devices. For example, in April 2023, Varco Leg Care, a consumer health-tech firm based in India, was granted FDA De Novo approval for their NTX100 Tonic Motor Activation (TOMAC) System. The NTX100 Tonic Motor Activation (TOMAC) System is designed for treating moderate to severe symptoms of RLS and improving sleep quality for patients resistant to medication. The device functions by electrically stimulating the peroneal nerves on both sides of the body to create tonic, long-lasting muscle activation which is compatible with sleep. This activation is efficient in suppressing the symptoms of Restless Leg Syndrome (RLS).

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21274

Which regions are emerging as leaders in the market?

Europe was the largest region in the restless leg syndrome market in 2024. North-America is expected to be the fastest-growing region in the forecast period. The regions covered in the restless leg syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Anemia and Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Stem Cell/Cord Blood Banking Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

Blood Bank Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-bank-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: